Skip to content

Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome

Phase 1 Study of Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02297022
Acronym
DBSPW
Enrollment
6
Registered
2014-11-21
Start date
2014-10-31
Completion date
2016-10-31
Last updated
2015-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prader-Willi Syndrome

Keywords

Deep Brain Stimulation, obesity, Prader-Willi syndrome

Brief summary

The purpose of this study is to investigate the safety and efficacy of deep brain stimulation in obese patients with Prader Willi syndrome refractory to conventional treatment.

Detailed description

The purpose of this study is to investigate the safety and efficacy of deep brain stimulation in obese patients with Prader Willi syndrome refractory to conventional treatment. Patients will be implanted with hypothalamic DBS electrodes. Calorimetric and anthropometric measures, body mass index, side effects, neuropsychiatric evaluations will be carried out at 6 months for measuring primary and secondary outcome. Side effects will be monitored at 1, 3, 6 and 12 months following surgery.

Interventions

DEVICEDeep Brain Stimulation

Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 15 years or older * Parents able to give informed consent * Diagnosis of Prader-Willi syndrome confirmed by genetic analysis * Refractoriness to medical treatment, defined as a weight loss lower than 10% of the body weight with nutritional, pharmacological or surgical interventions * Severe or morbid obesity * No contra-indications to the surgical procedure

Exclusion criteria

* Cardiovascular disease that might significantly increase the surgical risk * Brain lesions detected clinically or during MRI * Use of cardiac pacemakers/ defibrillators * Clinical conditions that may require the use of MRI in the post-operative period * Patients undergoing chemotherapy or immunosuppressive treatments * Patients unable to return to the hospital at the required intervals * Previous neurosurgical treatments that may increase the risk of DBS surgery * Active medical conditions that may require in-hospital treatment in the nearby future * Previous diagnosis of epilepsy or status epilepticus * Chronic infection * Plan to use diathermy * Metallic implants that might preclude MRI imaging of the brain * Active participation in other experimental studies

Design outcomes

Primary

MeasureTime frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability3 months
waist circumference; mid-upper arm circumference6 months
resting energy expenditure6 months
Body mass index6 months

Secondary

MeasureTime frame
daily food ingestion diary listing6 months
Child Yale-Brown Obsessive Compulsive Scale6 months
Child Behaviour Checklist6 months
Feeding Behaviour Questionnaire6 months

Countries

Brazil

Contacts

Primary ContactJuliana Yamashita
juliana.yamashita@hc.fm.usp.br551130617672

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026